Similarly, among HER2-positive BC patients treated with adjuvant trastuzumab, the persistence of HER2-negative or weakly positive CTCs may suggest a therapy-induced selection of HER2-negative tumor cells while the persistence of HER2-overexpressing CTCs could indicate a resistance to this type of treatment [23]. Here, ERBB2 is linked to breast cancer.